Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.

  • Authors:
    • M F Burbridge
    • L Kraus-Berthier
    • M Naze
    • A Pierre
    • G Atassi
    • N Guilbaud
  • View Affiliations

  • Published online on: December 1, 1999     https://doi.org/10.3892/ijo.15.6.1155
  • Pages: 1155-1217
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In an attempt to improve the relevance of human tumour xenografts to the clinical situation, we have established 3 models of human ovarian carcinoma (IGROV1, A2780 and NIH:OVCAR-3) in nude mice in which progressive peritoneal carcinomatosis resulted in the death of tumour-bearing animals (median survival times: 32, 40 and 64 days, respectively). Histological analyses revealed both common and different characteristics in growth patterns and dissemination profiles. In each case, three stages of the disease were defined (early, intermediate and late). The antitumour activities of adriamycin, cisplatin, cyclophosphamide and paclitaxel were then compared when administered at the early stage where small multifocal tumour nodules were detectable in the peritoneal cavity of the animals. Significant antitumour activities of cisplatin and particularly paclitaxel were noted in terms of increase in survival time of the treated mice (T/C values for IGROV1, A2780 and NIH:OVCAR-3 respectively: 152%, 167%, and 187% for cisplatin and 211%, 179% and >283% for paclitaxel), paclitaxel being curative against the NIH:OVCAR-3 xenograft. These results reflect the high efficacy of these two drugs in the clinic in the treatment of ovarian carcinoma. The clinically used CA125 tumour marker, not detectable in healthy mice, was measured in the serum of mice bearing IGROV1 and NIH:OVCAR-3 tumours. CA125 serum levels increased as a function of time and were well correlated to disease progression. Moreover, treatment with cisplatin and paclitaxel led to significant decreases in these levels of between 58% and 100%. This human serum marker could be used to predict early on the efficacy of chemotherapy in these two models. In conclusion, the three experimental ovarian carcinomas possess several important characteristics of the human disease and may thus be used as a screen to select new antitumour drugs potentially active in this pathology.

Related Articles

Journal Cover

Dec 1999
Volume 15 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Burbridge M, Kraus-Berthier L, Naze M, Pierre A, Atassi G and Guilbaud N: Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.. Int J Oncol 15: 1155-1217, 1999
APA
Burbridge, M., Kraus-Berthier, L., Naze, M., Pierre, A., Atassi, G., & Guilbaud, N. (1999). Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.. International Journal of Oncology, 15, 1155-1217. https://doi.org/10.3892/ijo.15.6.1155
MLA
Burbridge, M., Kraus-Berthier, L., Naze, M., Pierre, A., Atassi, G., Guilbaud, N."Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.". International Journal of Oncology 15.6 (1999): 1155-1217.
Chicago
Burbridge, M., Kraus-Berthier, L., Naze, M., Pierre, A., Atassi, G., Guilbaud, N."Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.". International Journal of Oncology 15, no. 6 (1999): 1155-1217. https://doi.org/10.3892/ijo.15.6.1155